Eribulin differentiates cetuximab resistant oral squamous cell carcinoma cells to sensitive by inducing mesenchymal–epithelial transition (MET). (July 2016) - Kitahara, H.; Hirai, M.; Nakamura, H.; Kawashiri, S.